BRITISH SOCIETY FOR HAEMATOLOGY

XXXVI World Congress International Society of Haematology

 

18-21 April 2016 Glasgow
Close
N. Poster
Poster title
Applicant name
Status
  42-P Development of a long-acting granulocyte colony stimulating factor molecule Hadel Ghaban Received Received
  45-P Impact of immunoparesis and altered serum free light chain ratio (ASFLCR) on the progression of monoclonal gammopathy of undetermined significance (MGUS ) in a district general hospital in the United Kingdom Buddhika Badugama Received Received
  46-P Anti-coagulation DATIX incident reporting audit Christopher Broadfield Received Received
  47-P Clinical pharmacist-provided services in iron overloaded beta-thalassemia major children; a new insight to patient care Salma Bahnasawy Received Received
  48-P How do myeloma patients experiences before and during diagnosis compare to those for all cancers? Findings from secondary analysis of the National Cancer Patient Experience Survey 2014 Sarah Richard Received Received
  49-P Assessing the applicability of a blood test guide in Accident and Emergency to optimise blood test requesting and achieve value for money Assia Merzougui Received Received
  51-P Review of use and implementation of the 2015 BCSH guidelines for the prophylaxis and treatment of tumour lysis syndrome in patients with haematological malignancy at University Hospitals Bristol Rebecca Oliver Received Received
  54-P EphB4 enhances bone marrow stromal stem cell-mediated support of haematopoiesis Thao Nguyen Received Received
  60-P The clinical utility of reticulocyte haemoglobin equivalent (Ret-He) and red cell distribution width (RDW-CV) in patients with polycythaemia vera Reginah Paradza Received Received
  67-P The Limitations of a Generic Chemotherapy Consent form: Improving Chemotherapy Consent with the Use of Regimen-Specific Consent Forms Caroline Watson Received Received
  68-P The Latin American experience allografting patients with severe aplastic anaemia: Real-world data on the impact of stem cell source and ATG administration Perla Colunga Received Received
  71-P Critical care of patients with haematological malignancies a retrospective analysis of one tertiary centres experience Alasdair Duguid Received Received
  72-P A gain-of-function variant in DIAPH1 is associated with heritable macrothrombocytopenia and sensorineural deafness Sarah Westbury Received Received
  87-P CellCountr: An online workspace for streamlining the interpretation of bone marrow aspirates - case study of use in a teaching hospital diagnostic laboratory. https://cellcountr.com Duncan Brian Received Received
  89-P Age and gender effect on osteonecrosis in sickle cell disease Hassan Al-Jafar Received Received
  91-P Reversal of coagulation markers in patients on dabigatran by prothrombin complex concentrate: A meta analysis Bryony Rudd Received Received
  92-P Prevalence of genetic variations in SERPINC1 gene in Indian deep vein thrombosis population with type I antithrombin deficiency TEENA BHAKUNI Received Received
  94-P Is there a need for a community anticoagulant monitoring service for the new direct acting oral anticoagulants? David Rhead Received Received
  100-P Preventing hospital acquired thrombosis in medical patients at a district general hospital: Compliance with National Institute for Health and Care Excellence (NICE) guidance Rosanna Ghinai Received Received
  101-P External quality assurance (EQA) for thromboelastography (TEG) and thromboelastometry (Rotem) Dianne Kitchen Received Received
  103-P Validity of two-level Wells score in predicting lower limb deep vein thrombosis and the risk of developing hospital aquired thrombosis in hospitalised patients at National Hospital of Sri Lanka Nadishani Ediriwickrama Received Received
  107-P Global tests of blood clotting during asparaginase treatment for acute lymphoblastic leukaemia. Preliminary results of the GlobALL study Kate Burley Received Received
  109-P Low-dose rituximab in combination with eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Perla Colunga Received Received
  110-P A retrospective study assessing the incidence of hospital acquired thrombosis over an eight year period spanning the introduction of mandatory venous thromboembolism (VTE) risk assessment Michelle Melly Received Received
  112-P Effect of extremes of body weight on efficacy and safety of rivaroxaban in the treatment of venous thromboembolism; real life experience Deepa Arachillage Received Received
  113-P Missed VTE Risk Assessments at Aintree University Hospital Trust: A Retrospective Analysis Julia Parton Received Received
  116-P Evaluation of a simplified procedure for EQA samples: First survey results for the point of care testing (POCT) INR EQA for CoaguChek, XS Plus & XS Pro users Shelene Munroe-Peart Received Received
  117-P Commutability of samples used to assess assays for direct oral anticoagulants (DOACS): Data from UK NEQAS for Blood Coagulation multicentre studies Ian Jenningsi Received Received
  118-P Point of care ddimer testing in practice: Survey results for ddimer testing performed in patient care within the United Kingdom Lilia Brown Received Received
  119-P Von Willebrand factor (VWF) assays and the diagnosis of von Willebrand disease (VWD). Who follows the guidelines? Ian Jennings Received Received
  120-P Continued discrepancies between protein S activity assays? Ian Jennings Received Received
  121-P Identifying factors that influence the agreement between platelet function tests in patients on P2Y12-inhibitors with a high bleeding risk Minka Vries Received Received
  122-P Venous thromboembolism in cardiac surgery: Comparing emergency to planned admissions over five years Huw Rowswell Received Received
  125-P An audit of thromboprophylaxis and venous thromboembolism rates in myeloma patients at Kings College Hospital Zara Sayar Received Received
  126-P Use of age adjusted d-dimer monitoring to assist the withdrawal of anticoagulation following unprovoked pulmonary embolism Kathryn Musgrave Received Received
  127-P Is there any clinical or biological difference that distinguishes recurrence from non-recurrence after idiopathic PE? Matthew Alley Received Received
  132-P Modified computer assisted strain gauge plethysmography (venometer V3) can safely decrease the need for compression ultrasound scanning in patients with suspected deep vein thrombosis Andrew Hughes Received Received
  133-P The use of age-adjusted d-dimer in patients over 50 years old presenting with a suspected deep vein thrombosis can safely decrease the need for compression ultrasound scanning Andrew Hughes Received Received
  134-P A survey of the management of venous thrombosis in cancer associated thrombocytopenia Catherine Hildyard Received Received
  136-P Continuation of eculizumab in atypical haemolytic syndrome (aHUS) patients without renal recovery or an identified complement defect Rebecca Shaw Received Received
  138-P Effects of rivaroxaban and apixaban on routine coagulation screening tests Sean Platton Received Received
  139-P Evaluation of diagnostic delay in a cohort of individuals with acquired haemophilia A Aishah Anwar Received Received
  142-P The relevance of placental infarction for subsequent pregnancies following stillbirth Sarah Wharin Received Received
  143-P Single UK tertiary neonatal unit experience of neonatal arterial thrombosis Jean Yong Received Received
  156-P The impact of TTP specialist centres on patient survival and satisfaction Ryan Low Received Received
  158-P Assessment of deep venous thrombosis referrals in an ambulatory emergency care unit : A single centre study Rodothea Amerikanou Received Received
  159-P The DAWN 4S VTE module - an electronic tool and record for deep vein thrombosis (DVT) assessment, diagnosis, treatment and follow up Jane Strong Received Received
  160-P Validation of the use of age adjusted d-dimer cut off values to reduce the compression venous ultrasound rates in an acute ambulatory DVT service Jane Strong Received Received
  161-P A snapshot of anticoagulation in a district general hospital ruth cumber Received Received
  162-P Dilute Russells viper venom time potential use for the detection of apixaban and rivaroxaban predicted from interference in lupus anticoagulant testing Sean Platton Received Received
  166-P Outcomes of patients treated for cancer or chemotherapy associated venous thromboembolism and effectiveness of secondary prevention DAVID MCCLINTON Received Received
  168-P DOACs: Common and uncommon errors. A brief patient safety intervention and review. Victoria Ware Received Received
  169-P The introduction of Laboratory based TEG testing: Could South Tees NHS Foundation Trust introduce an individualised goal-directed therapy supporting effective blood management Daniella M Winterburn Received Received
  177-P Impact of adhesion molecules expression on nodal and extra-nodal involvement in chronic lymphocytic leukemia Azza Kamel Received Received
  180-P Impact of the apoptotic regulator DRAK2 in chronic lymphocytic leukemia Carmela Ciardullo Received Received
  189-P Dysregulation of CCN1 expression in conjunction with increased expression of p21CIP1 and p27KIP1 implicated in mantle cell lymphoma progression Afak Zaidi Received Received
  193-P A comparison of PCR methods for the detection of MYD88 L265P mutations in a diagnostic setting Jamal Anwar Received Received
  196-P Efficacy of different chemotherapy regimens in primary mediastinal large B-cell lymphoma Inga Ilyasova Received Received
  197-P What is the best route for methotrexate delivery to reduce the incidence of central nervous system relapse in diffuse large B-cell lymphoma? A review of our practice at University Hospital Aintree, Liverpool Jonathan Heseltine Received Received
  198-P Efficacy and safety of RCEOP chemotherapy in patients with diffuse large cell lymphoma (DLCL) not fit for anthracyclines are comparable to RCHOP Danya Abdulwahid Received Received
  200-P Diagnosing light chain (AL) amyloidosis on temporal artery biopsies for suspected giant cell arteritis Rosanna Ghinai Received Received
  205-P The NCRI Myeloma XI trial for newly diagnosed symptomatic multiple myeloma (NDMM); second primary malignancy (SPM) incidence when lenalidomide is used as an induction and maintenance treatment option John Jones Received Received
  208-P Experience of lenalidomide use in the treatment of myeloma at North Bristol NHS Trust - increasing number of dose modifications is associated with increased overall survival Julia Wolf Received Received
  209-P The addition of rituximab to CODOX-M & IVAC in first line therapy of poor risk Burkitt lymphoma (IPI 3-5) yields an excellent outcome: A phase 2 UK NCRI / Bloodwise Trial (LLR 04058) Andrew McMillan Received Received
  210-P Front line therapy with R-CODOX-M & R-IVAC in poor risk diffuse large B cell lymphoma (IPI 3-5) yields a good outcome without transplantation: A phase 2 UK NCRI / Bloodwise Trial Andrew McMillan Received Received
  215-P Audit of thromboprophylaxis for patients with multiple myeloma on treatment with immunomodulatory drugs Guy Pratt Received Received
  216-P Intrathecal chemotherapy prophylaxis for diffuse large B cell lymphoma (DLBCL): Real-life clinical practice in the face of conflicting guidelines and a weak evidence base Yooyun Chung Received Received
  217-P Is toxicity and inpatient admission time reduced with recently introduced GDP salvage chemotherapy compared to IVE and DHAP chemotherapy? A retrospective review of relapsed and refractory lymphoma patients in the Northern region of England Jennifer Orr Received Received
  225-P Population-based study of patients with mantle cell lymphoma; era by era improvement in survival mediated by first-line rituximab and autologous stem cell transplantation Komal Joshi Received Received
  228-P Focal segmental glomerulosclerosis: A paraneoplastic phenomenon of mantle cell lymphoma David Sparksman Received Received
  232-P Subcutaneous rituximab can be safely administered without pre-medication Samuel Burrows Received Received
  243-P A dramatic response to lenalidomide based chemotherapy in a patient with multiple relapsed GCB-subtype diffuse large B cell lymphoma post allogeneic stem cell transplant Philip George Received Received
  248-P An update on prospective audit of rivaroxaban as prophylaxis and treatment during myeloma therapy with immunomodulatory drugs (IMiDs) at East Kent Hospitals University NHS Foundation Trust Catherine Roughley Received Received
  249-P Hepatotoxicity with pegylated-asparaginase in acute lymphoblastic leukaemia is influenced by raised body mass index Kanchana De Abrew Received Received
  255-P Tumour lysis risk assessment and prophylaxis for high grade lymphoma in a large university hospital - an audit against BCSH Guidelines Emily Chernucha Received Received
  257-P The cost of myeloma: A gap analysis in the diagnostic work-up of multiple myeloma at Gloucestershire Hospitals NHS Foundation Trust Marquita Camilleri Received Received
  265-P Nodular Lymphocyte Predominant Hodgkin Lymphoma: A retrospective review of consecutive cases managed through a single MDT in the East of England between 1999 and 2015. Jessica Griffin Received Received
  266-P A single centre experience of DPACE-based therapy with lenalidomide or thalidomide /- bortezomib prior to autologous transplant in myeloma Kanchana De Abrew Received Received
  272-P A retrospective review of CNS prophylaxis in diffuse large B cell lymphoma in two district Angharad Pryce Received Received
  273-P The evolution of first line treatment of multiple myeloma - a retrospective review of overall survival and time to second treatment Alice Hart Received Received
  281-P Assessment of DNA damage and DNA damage response and repair in dormant leukaemic cells SAHAR ALDOSARI Received Received
  283-P Reduced Fas-associated phosphatase-1 expression in patients with acute myeloid leukaemia Nahla Osman Received Received
  290-P T cell subsets do not alter on decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: Data from the DESTINY trial Gemma Austin Received Received
  292-P Small molecule inhibitors against PI3K/Akt/mTOR and NF-kB signaling pathways as a combinatorial approach in acute myeloid leukemia treatment Andre G Deslauriers Received Received
  294-P Germline heterozygous DDX41 variants account for a subset of familial myelodysplasia and acute myeloid leukaemia Shirleny Cardoso Received Received
  295-P Ribosomal protein S6 dephosphorylation is a rapid broad-spectrum biomarker for therapeutic targeting of leukaemia cells Martin Grundy Received Received
  304-P Prospective study of trough imatinib levels in newly diagnosed chronic myeloid leukaemia (CML) patients and its correlation with response Charles Agbuduwe Received Received
  309-P Risk of cardiovascular disease (CVD) in chronic myelogenous leukemia (CML) patients from community-based oncology practices Anna Dsouza Received Received
  310-P Status of persistent, grade 1/2 imatinib-related adverse events (AEs) in chronic phase chronic myeloid leukemia (CML-CP) patients after switching to dasatinib (DASPERSE/CA180-400) Megan McNamee Received Received
  311-P The use of ruxolitinib in the treatment of myelofibrosis: A review of clinical practice and response in a single teaching hospital Sara Elhag Received Received
  312-P Thiamine deficiency is uncommon in patients with myeloproliferative neoplasms Natalia Curto-Garcia Received Received
  315-P Danazol as first-line therapy for myelodysplastic syndromes Perla Colunga Received Received
  329-P CNS demyelination in patients on nilotinib treatment for CML A Pryce Received Received
  331-P A review of new diagnoses of haematological malignancies within the Leicestershire, Northamptonshire and Rutland region Lucinda Sanders Received Received
  332-P Implementation of high throughput sequencing in an integrated laboratory: Experience from the Haematological Malignancy Diagnostic Service (HMDS) Jan Taylor Received Received
  340-P Unlocking the Potential of Coagulation Clinical Nurse Specialists Sinead Brookman Received Received
  344-P The impact of immune thrombocytopenia on health-related quality of life in children Charlotte Colam Received Received
  348-P Presentation, course and outcome of langerhans cell histiocytosis in children Fauzia khan Received Received
  349-P Leukostasis and tumor lysis syndrome in childrens leukaemia admitted to an intensive care unit diana mota Received Received
  350-P Review of an internal quality assurance programme for transcranial doppler (TCD) screening in children with sickle cell disease. Experiences from Barts Health NHS Trust Banu Kaya Received Received
  357-P Treating sickle cell acute pain crisis at a busy London emergency department Rodothea Amerikanou Received Received
  358-P Investigation of Anaemia in Patients Admitted to a Medicine of the Elderly Unit Angus Killean Received Received
  361-P Fat embolism syndrome in 3 patients with sickle cell disease Angela Collins Received Received
  366-P Hydroxyurea and sickle cell disease: Do we need to reach the maximally tolerated dose (MTD)? Wesam AL-SAKKAF Received Received
  375-P A life-threatening autoimmune hemolytic anemia in a patient with newly-diagnosed pulmonary sarcoidosis Angeliki Ntineri Received Received
  377-P Decreased SOD2 mRNA levels in peripheral blood cells from steady-state sickle cell disease patients I.A. Armenis Received Received
  379-P Annual review of transfusion targets in regularly transfused paediatric and adult sickle cell patients. Experiences from Barts Health NHS Trust Kaya Banu Received Received
  381-P Seroepidemiology of hepatitis B, C & HIV among blood donors in Jos, North-Central Nigeria A. Michael ONOJA Received Received
  382-P Public involvement in clinical research: Lessons from a cluster-randomised trial Stephen Hibbs Received Received
  383-P Sustained effect on compliance with transfusion guidelines of a combination of direct feedback about practice and an electronic decision support process Juliet Smith Received Received
  384-P A descriptive single centre experience of the management and outcome of maternal alloantibodies in pregnancy Natalie Heeney Received Received
  385-P The impact of the implementation of an electronic prescribing system on the use of single unit transfusions in an acute haematology ward Juliet Smith Received Received
  389-P Changing patterns of off-licence use of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of major haemorrhage Jennifer Orr Received Received
  391-P A red cell dosage calculator could promote single unit red cell transfusion, prevent over-transfusion and reduce red cell usage Sharran Grey Received Received
  392-P Optimisation of Preoperative Anaemia in Patients Undergoing Elective Cardiac Surgery NADIA BLUNT Received Received
  394-P Tertiary Neonatal Single Centre Experience of Fresh Frozen Plasma Transfusion - an Audit of Current Practice Sarah Dillon Received Received
  400-P Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients Claudia Monica Gorcea Received Received
  401-P Is there any difference in line infection rates between Hickmann and internal jugular/subclavian central lines in stem cell transplant patients? Claire Stockdale Received Received
  404-P Donors who are heavier than their recipient, male, have a BMI 30 or are younger provide the best chance of meeting the requested cell dose for PBSC transplantation Annelies Billen Received Received
  406-P Outcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation (non-transplant consolidation NTC) therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) John Ashcroft Received Received
  407-P Donor cell t(8;21) AML after allogeneic unrelated donor hematopoietic stem cell transplantation for infant ALL SABET IMAN Received Received
  412-P An audit of stopping antifungal prophylaxis post allogeneic stem cell transplantation. POOJA PAREKH Received Received
  527-P Identifying and prioritising treatment uncertainties in blood transfusion through the James Lind Alliance Mike Murphy Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon - Fri 8:15 - 15:00
08:52
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

BRITISH SOCIETY FOR HAEMATOLOGY

XXXVI World Congress International Society of Haematology

 

18-21 April 2016 Glasgow
HELP LINE
Manage Orders
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 18/04/2016 TO 18/04/2017
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.BSH2016.2016 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 04/04/2016
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster





PosterSessionOnline
Logo Draft
 
Logo Cert